Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

TCT 2021 | A simplified comorbidity index to predict mortality in allo-HCT recipients

Comorbidity burden is a key consideration in determining risk in patients receiving allogeneic hematopoietic cell transplantation (allo-HCT). In this interview, Roni Shouval, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the results of a single-center retrospective analysis evaluating the influence of comorbidities in patients undergoing transplantation. This interview took place during the Transplantation & Cellular Therapy (TCT) 2021 Meetings.